<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">20980521</PMID>
        <DateCompleted>
            <Year>2011</Year>
            <Month>01</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-5514</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>85</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of virology</Title>
                <ISOAbbreviation>J. Virol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Characterization of cross-reactive CD8+ T-cell recognition of HLA-A2-restricted HIV-Gag (SLYNTVATL) and HCV-NS5b (ALYDVVSKL) epitopes in individuals infected with human immunodeficiency and hepatitis C viruses.</ArticleTitle>
            <Pagination>
                <MedlinePgn>254-63</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01743-10</ELocationID>
            <Abstract>
                <AbstractText>The immunologic mechanisms underlying the faster progression of hepatitis C virus (HCV) disease in the presence of human immunodeficiency virus (HIV) coinfection are not clearly understood. T-cell cross-reactivity between HCV and influenza virus-specific epitopes has been associated with rapid progression of HCV disease (S. Urbani, B. Amadei, P. Fisicaro, M. Pilli, G. Missale, A. Bertoletti, and C. Ferrari, J. Exp. Med. 201:675-680, 2005). We asked whether T-cell cross-reactivity between HCV and HIV could exist during HCV/HIV coinfection and affect pathogenesis. Our search for amino acid sequence homology between the HCV and HIV proteomes revealed two similar HLA-A2-restricted epitopes, HIV-Gag (SLYNTVATL [HIV-SL9]) and HCV-NS5b (ALYDVVSKL [HCV-AL9]). We found that 4 out of 20 HLA-A2-positive (HLA-A2(+)) HIV-infected individuals had CD8(+) T cells that recognized both the HIV-SL9 and HCV-AL9 epitopes. However, the AL9 epitope was generally shown to be a weak agonist. Although HCV-monoinfected individuals in our study did not show AL9-specific responses, we found that about half of HCV/HIV-coinfected individuals had dual responses to both epitopes. High dual T-cell recognition among coinfected subjects was usually due to separate T-cell populations targeting each epitope, as determined by pentamer staining. The one individual demonstrating cross-reactive T cells to both epitopes showed the most advanced degree of liver disease. In coinfected individuals, we observed a positive correlation between the magnitudes of T-cell responses to both the SL9 and the AL9 epitopes, which was also positively associated with the clinical parameter of liver damage. Thus, we find that HIV infection induces T cells that can cross-react to heterologous viruses or prime for T cells that are closely related in sequence. However, the induction of cross-reactive T cells may not be associated with control of disease caused by the heterologous virus. This demonstrates that degeneracy of HIV-specific T cells may play a role in the immunopathology of HCV/HIV coinfection.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Vali</LastName>
                    <ForeName>Bahareh</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Medical Science, University of Toronto, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tohn</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cohen</LastName>
                    <ForeName>Michael J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sakhdari</LastName>
                    <ForeName>Ali</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sheth</LastName>
                    <ForeName>Prameet M</ForeName>
                    <Initials>PM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yue</LastName>
                    <ForeName>Feng Yun</ForeName>
                    <Initials>FY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wong</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kovacs</LastName>
                    <ForeName>Colin</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaul</LastName>
                    <ForeName>Rupert</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ostrowski</LastName>
                    <ForeName>Mario A</ForeName>
                    <Initials>MA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <Agency>Canadian Institutes of Health Research</Agency>
                    <Country>Canada</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>10</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Virol</MedlineTA>
            <NlmUniqueID>0113724</NlmUniqueID>
            <ISSNLinking>0022-538X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015683">Gene Products, gag</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015789">HLA-A2 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015683" MajorTopicYN="N">Gene Products, gag</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015789" MajorTopicYN="N">HLA-A2 Antigen</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>10</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>10</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>1</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20980521</ArticleId>
            <ArticleId IdType="pii">JVI.01743-10</ArticleId>
            <ArticleId IdType="doi">10.1128/JVI.01743-10</ArticleId>
            <ArticleId IdType="pmc">PMC3014184</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Exp Med. 2000 May 1;191(9):1499-512</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10790425</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Exp Med. 2001 Jan 15;193(2):181-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11148222</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2001 Aug 15;33(4):562-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11462196</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2001 Dec;75(23):11392-400</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11689620</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Immunol. 2002 Jul;3(7):627-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12055626</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Immunol. 2002 Jun;2(6):417-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12093008</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2003 Aug;38(2):518-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12883497</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Immunol. 2004 Jan;34(1):194-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14971045</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Exp Med. 1966 Sep 1;124(3):331-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">5922742</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 1986 Mar 28;44(6):959-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2420472</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Exp Med. 1994 Jun 1;179(6):1933-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8195718</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 1998 Jul 30;394(6692):482-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9697771</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Exp Med. 1998 Nov 2;188(9):1705-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9802982</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Exp Med. 2005 Mar 7;201(5):675-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15753202</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>HIV Med. 2005 Nov;6(6):375-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16268817</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2005 Dec;115(12):3602-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16308574</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Immunol Rev. 2006 Jun;211:164-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16824126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>AIDS. 2007 Nov 30;21(18):2541-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18025895</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2008 Mar;118(3):1143-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18246203</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Infect Dis. 2008 May 15;197(10):1394-401</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18444797</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>AIDS. 2008 Oct 1;22(15):1979-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18784461</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2008;3(10):e3454</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18941622</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Hepatol. 2009 Jan-Mar;8(1):26-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19221530</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Immunity. 2009 Dec 18;31(6):849-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20064442</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Gastroenterol. 2010 Jun;105(6):1346-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20179698</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Immunity. 1999 Dec;11(6):733-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10626895</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>